Lazcluze

J&J bolsters Rybrevant-Lazcluze's case against AZ's Tagrisso with survival analysis
Fierce Pharma
Sun, 09/8/24 - 11:38 pm
JNJ
Rybrevant
Lazcluze
AstraZeneca
Tagrisso
non-small cell lung cancer
Targeting AZ's Tagrisso, Johnson & Johnson's Rybrevant combo wins key FDA nod in first-line lung cancer
Fierce Pharma
Tue, 08/20/24 - 11:36 am
JNJ
AstraZeneca
FDA
non-small cell lung cancer
Rybrevant
Lazcluze
Tagrisso